A Cooler Path Through Chemo: Partnership Unlocks Key Side Effect Solution

WILMINGTON, Del. – June 18, 2026 – For many cancer patients, the fight is not just against the disease, but against the brutal side effects of the treatment designed to save them. Among the most common and debilitating is oral mucositis (OM), a painful inflammation and ulceration of the mouth lining that can make eating, drinking, and even speaking an agonizing ordeal. Affecting up to 80% of individuals undergoing certain chemotherapy regimens, OM is more than a discomfort; it can lead to malnutrition, dangerous infections, and dose-limiting toxicities that force doctors to pause or abandon life-saving therapies.

For years, management has been limited to pain relief and oral hygiene, a reactive approach to a predictable problem. But a patient-driven innovation is changing that calculus. Now, a new partnership aims to dismantle the administrative hurdles that have kept this solution from the patients who need it most, illustrating a powerful strategy for translating medical breakthroughs into tangible differences in care.

The Science of Comfort: An Evidence-Backed Innovation

At the heart of this shift is the Chemo Mouthpiece®, a self-contained oral cryotherapy device developed by Chemomouthpiece, LLC. The principle is elegantly simple: by cooling the entire oral cavity during and after chemotherapy infusion, the device induces vasoconstriction—a narrowing of the blood vessels. This process reduces the amount of potent chemotherapy drugs that reach the delicate mucosal tissues of the mouth, mitigating the cellular damage that leads to mucositis.

The device is not just a concept; it's an FDA-cleared and clinically validated tool. After earning a coveted Breakthrough Device Designation in 2021, the Chemo Mouthpiece® received FDA 510(k) clearance in January 2024. Its efficacy was substantiated in a multi-institutional randomized controlled trial published in Supportive Care in Cancer, the official journal of the Multinational Association of Supportive Care in Cancer (MASCC).

The results from that study are compelling. Patients using the device experienced a 46% reduction in patient-reported oral pain. Even more significantly, there was a 68% reduction in the need for opioids and other analgesics, a critical outcome in an era focused on reducing opioid dependency. The device proved effective across a wide range of cancer types and chemotherapy regimens and was overwhelmingly well-received by patients, with 83% stating they would recommend it to others.

This level of evidence elevates the device from a hopeful idea to a proven intervention, one that offers a proactive strategy to prevent a painful side effect rather than simply managing its aftermath.

The Last-Mile Problem: From Clearance to Patient Care

However, in the complex landscape of American healthcare, FDA clearance is often just the beginning of a long journey. For a medical device to make a real-world impact, it must navigate a gauntlet of logistical and administrative challenges. Busy oncology practices, already stretched thin, are tasked with managing prescribing, conducting benefits investigations, submitting prior authorization requests to insurers, and onboarding patients—a time-consuming process that can create significant delays or prevent access altogether.

This “last-mile problem” is a well-known barrier in healthcare innovation. An effective tool can exist, but if the pathway to the patient is clogged with administrative friction, its potential remains unrealized. This is precisely the challenge that Chemomouthpiece, LLC, a company founded by a cancer survivor with a mission to improve supportive care, sought to solve.

“Our mission has always been to help patients better manage one of the most painful and clinically disruptive side effects of chemotherapy treatment,” said Frank Jacobucci, Chief Commercial Officer of Chemomouthpiece, LLC. Recognizing that the device's impact depended on seamless access, the company looked for a partner who specialized in untangling these logistical knots.

A Strategic Alliance to Bridge the Access Gap

Enter Zeal Specialty Pharmacy. The Pittsburgh-based, nationally licensed pharmacy has built its reputation on a technology-driven model designed to handle complex patient care logistics for rare and debilitating conditions. With dual accreditation and a Rare Disease Center of Excellence designation, Zeal specializes in the very services that can overwhelm a typical medical practice: coordinating prescriptions, navigating insurance formularies, managing patient assistance programs, and ensuring therapies get into patients' hands quickly.

The new partnership announced today leverages the distinct expertise of both organizations. Chemomouthpiece, LLC provides the clinically proven medical device, while Zeal Specialty Pharmacy provides the integrated service layer to ensure it reaches the patient. Under the agreement, Zeal will act as a central hub for oncology practices, handling the entire access and onboarding process. When a provider prescribes the Chemo Mouthpiece®, Zeal will manage the benefits investigation, prior authorization support, patient onboarding, and even coordination for Patient Assistance Programs (PAP).

“Oral mucositis is one of the most painful and under-supported side effects of chemotherapy, and until now patients have had few real ways to manage it,” explained Jonathan Ogurchak, PharmD, CSP, and CEO of Zeal Specialty Pharmacy. “Partnering with Chemomouthpiece lets us do exactly what Zeal was built to do: get the Chemo Mouthpiece into patients' hands and give oncology practices one coordinated source for access and support. For us, that's what optimizing the patient experience really means.”

Redefining the Standard of Supportive Care

This collaboration represents more than a simple business deal; it’s a strategic redesign of the care delivery process. By absorbing the administrative burden, the partnership allows oncology teams to focus on clinical care, not paperwork. For patients, it means faster, more reliable access to a tool that can dramatically improve their quality of life during one of the most challenging experiences imaginable.

The goal, as Jacobucci noted, is to get the device to patients “early in their treatment journey, ideally before chemotherapy begins.” This proactive approach is a fundamental shift in supportive oncology. It moves beyond reacting to side effects and toward actively preventing them, helping patients maintain their nutrition, avoid secondary infections, and, most importantly, stay on their prescribed cancer treatment schedules.

For the thousands of patients diagnosed with cancer each year, innovations like the Chemo Mouthpiece® offer profound hope. But it is strategic partnerships like this one—focused on dismantling the unseen barriers within the healthcare system—that turn that hope into a tangible reality, ensuring that the best solutions don't just exist, but are accessible to all who need them.